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The use of plants for the production of vaccine is one of the important applications in 
the modern medicine. There are many advantages of using plants as the production system 
compared to traditional mammalian system. Many plant species have been exploited to 
accumulate vaccine antigens for human infectious diseases, and vaccine candidates are 
approaching the market. The transgenic plants are considered as cheap source and found 
alternative approach to fermentation for large-scale production of vaccine antigens. The 
autotrophic growth of plants requires only soil minerals, water, nitrogen, sunlight energy for 
the synthesis of vaccine antigens. Therefore, vaccine production by using plants is one of the 
cheap and efficient technologies. This review covers the recent advances of plant derived 
vaccine antigens for the prevention of human infectious diseases and focuses on the current 
methods. 
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The use of vaccines against many 
human infectious diseases is one of the direct 
applications of biotechnology in the modern 
medicine. The most cost-effective approach 
for prevention of many human infectious 
diseases is via vaccination. However, the high 
cost of vaccination makes it unaffordable for 
immunization of people living in developing 
countries (Davoodi-Semiromi et al. 2009, 2010; 
Bock and Warzecha, 2010; Gomez et al. 2010; 
Daniell et al. 2009; Rybicki, 2010; Malabadi et 
al. 2011). Currently, vaccine production  is 
very expensive for many reasons, due to their 
complex production system, route of 
administration, expensive fermentation 
systems, prolonged purification steps, 
additional expenses associated with adjuvant, 
cold storage, transportation and sterile 
delivery (Davoodi-Semiromi et al. 2009, 2010; 
Rybicki, 2010; Daniell et al. 2009). Most 
vaccines in use today are based on killed or 
attenuated whole bacteria or viruses, which 
might cause a risk of infection by the 
microorganisms during the vaccination 
(Rybicki, 2010).   
 




Exploiting plants as biological 
bioreactors for the production and delivery of 
subunit vaccines is an exciting and promising 
application of biotechnology (Korban, 2002; 
Hiatt et al. 1989; Hellwig et al. 2004; Vermij 
and Waltz, 2006; Malabadi, 2008; Tiwari et al. 
2009; Rybicki, 2010; Malabadi et al. 2010; 
Malabadi et al. 2011). Plant derived green 
vaccines eliminate the expenses associated 
with fermenters, purification, adjuvant, cold 
chain logistics, storage/transportation, needle 
free-administration, and sterile delivery 
(Davoodi-Semiromi et al. 2009, 2010; 
Walmsley and Arntzen, 2003; Pascual, 2007; 
Malabadi, 2008; Daniell et al. 2009; Gomez et 
al. 2010). Safety is one of the important issue 
in any clinical trial, and plant derived vaccine 
antigens could offer higher safety because 
they are needle/syringe free. Alternately, 
green vaccines would also reduce the need 
for trained medical personnel to administer 
the vaccine (Vermij and Waltz, 2006; Lal et al. 
2007; Pascual, 2007; Tiwari et al. 2009; 
Malabadi et al. 2011). Plant derived vaccine 
antigens are less contaminated with human 
and animal pathogenic microorganisms than 
those derived from animal cells, because 
plants are not hosts for human infectious 
agents (Giddings et al. 2000; Ma et al. 2004; 
Desai et al. 2010; Malabadi et al. 2010). One 
more advantage is that if the vaccine is 
delivered orally, the plant cell would protect 
the antigen from the acidic environment 
/enzymes of the stomach because of the bio-
encapsulation of antigen by the plant cell 
walls (Daniell et al. 2009; Thanavala et al. 
1995; Malabadi, 2008; Davoodi-Semiromi et 
al. 2009, 2010; Malabadi et al. 2011). Plant cells 
are able to perform complex posttranslational 
modification of recombinant proteins, such as 
glycosylation and disulfide bridging that are 
often essential for biological activity of many 
mammalian proteins, allowing for the 
retention of native biological activity (Lienard 
et al. 2007; Mason et al. 1992, 1996; Ma et al. 
1997, 1998, 2004, 2005; Rybicki, 2010; 
Tremblay et al. 2010). Therefore, plants have 
been considered as an alternative production 
systems for subunit vaccines (Goldstein and 
Thomas, 2004; Haq et al. 1995; Malabadi, 2008; 
Hellwig et al. 2004; Chen and Liu, 2011; 
Phoolcharoen et al. 2011; Farrance et al. 2011; 
Mathew et al. 2011; Malabadi et al. 2011). 
Plant growth requirements are very simple 
since plants uses light as its energy source 
than mammalian or insect cell culture 
growth, resulting in a more robust and inert 
system for the production of subunit vaccines 
in different plant systems (Trembley et al.  
2010; Vermij and Waltz, 2006; Rybicki, 2010; 
Tiwari et al. 2009). The concept of using 
plants to produce vaccine antigens is 20 years 
old this year, and it would be used as an 
established technology (Rybicki, 2010). The 
plant- derived vaccine technology has proven 
its worth as a means of cheap, easily scalable 
production of materials (Arakawa et al. 1998; 
Ma et al. 1997, 1998, 2004, 2005; Tiwari et al. 
2009;  Hefferon, 2010; Daniell et al. 2009; Bock 
and Warzecha, 2010;Rybicki, 2010; Shoji et al. 
2011; Chen and Liu, 2011; Phoolcharoen et al. 
2011; Farrance et al. 2011; Penney et al. 2011; 
Mathew et al. 2011; Malabadi et al. 2011). 
Recently a novel technique developed by Icon 
Genetics (Bayer Crop science, Germany), 
based on the Magnifection, has additional 
advantageous than the routine methods used 
for the production of subunit vaccines in 
plants. This system allows very fast 
production, high recombinant protein 
expression levels for example hepatitis B 
virus (HB core) with an accumulation level 
exceeding 7% of total soluble protein  in 
tobacco (Gomez et al. 2010; Yusibov and 
Rabindran, 2008; Gleba et al. 2005;Huang et al. 
2006). Therefore, plant-derived vaccines 
could be used as a powerful weapon to 
combat infectious diseases (Tacket et al. 1998, 
2000; Sala et al. 2003). The reason for this is 
that the applications are based on established 
plant tissue culture protocols for many plants 
(Malabadi and Nataraja, 2002; Malabadi et al. 
 




2004; Malabadi et al. 2005; Malabadi and van 
Staden, 2005a, 2005b, 2005c; Malabadi and 
Nataraja, 2006; Malabadi et al. 2011), gene 
cloning and plant transformation technology 
(Maliga, 2004; Daniell et al. 2009; Daniell et al. 
2009; Bally et al. 2009; Tremblay et al. 2010; 
Malabadi and Nataraja, 2007a, 2007b; 
Malabadi et al. 2008a, 2008b, 2008c, 2008d), 
and that development requires relatively 
limited investment (Sala et al. 2003). Hence 
with the invention of modern plant genetic 
engineering techniques, unlimited number of 
transgenic plants can be produced under in 
vitro conditions. The seeds collected from 
these transgenic lines could be stored, and 
used as and when necessary for the molecular 
farming.   Furthermore plant DNA is not 
known to interact with the animal DNA and 
plant viral recombinants do not invade 
mammalian cells (Sala et al. 2003). Among the 
existing plant based technologies, there is one 
more method, which uses the plant viruses as 
expression vectors (Desai et al. 2010). Virus 
infected plants have been used to produce 
several antigenic proteins. This method has 
more advantages as compared to other 
methods due to the rapid onset of expression, 
and the systemic spread of virus so that 
protein is produced in every cell (Desai et al. 
2010). Plant systems also constitute a 
convenient oral delivery option, preventing 
the cost and inconvenience associated with 
purification and injections. Furthermore, the 
production of vaccine antigens in plants is 
economically advantageous and there is no 
risk of contamination by animal pathogens 
(Malabadi et al. 2011). 
 
Immunogenicity of plant derived vaccines 
Plant produced glycoproteins can lead 
to immunogenicity, affect its pharmacokinetic 
properties and certain regulatory issues (Ma 
et al. 2005; Sethurman and Stadheim, 2006; 
Lienard et al. 2007; Obembe et al. 2011; Desai 
et al. 2010). Recent advances made in genetic 
modification of glycosylating enzymes in 
plants have made it possible to add or 
remove desired sugars and make protein 
with desired glycosylation pattern similar to 
human (Desai et al. 2010; Malabadi et al. 
2011). It has been suggested that plant-
derived recombinant proteins or antibodies 
may have increased immunogenicity or 
allergenicity as compared to mammalian 
counterparts (Ma et al. 2005; Penney et al. 
2011). This is well explained by the fact that a 
state of tolerance or energy has been gained 
by the daily consumption of plant glycol-
proteins in our food (Ma et al. 2005). The 
antigenicity of plant glycans, or the 
immunogenicity of plant glycans is still a 
major concern in the context of plant proteins, 
there have been no published analyses in 
humans on the effect of immunizing with a 
mammalian protein bearing plant glycans 
(Ma et al. 2005). However, Large Scale 
Biology Corporation has examined 15 
patients who were systemically immunized 
with glycosylated single chain antibodies 
produced in plant and did not find serious 
adverse reactions (Dr. L. Grill, personal 
communication) (Ma et al. 2004, 2005).  In one 
of the human study of mucosal application of 
plant secretory antibody, no evidence for an 
immune response to the plant recombinant 
glycoprotein was detected after six 
applications of antibody (Ma et al. 1998; Ma et 
al. 2004; Ma et al. 2005; Desai et al. 2010). Plant 
glycan patterns may not represent a problem 
in terms of human health; they may affect 
conformational epitopes, or clearance of plant 
derived antibodies (Bakker et al. 2001; Ma et 
al. 2005). Comparison of plant and 
mammalian N-glycan biosynthesis indicates 
that 13 (1,4)-galactosyltransferase is the most 
important enzyme that is missing for 
conversion of typical plant N-glycans into 
mammalian-like N-glycans (Bakker et al. 
2001; Ma et al. 2005).  Expression of this key 
enzyme in transgenic tobacco resulted in 15% 
of proteins expressing terminal 13 (1, 4)-
galactose residues. Back-crossing of 13 (1, 4)-
 




galactosyltransferase with tobacco plants 
expressing murine Ig heavy and light chains 
resulted in expression of antibody exhibiting 
partially galactosylated N-glycans (Bakker et 
al. 2001; Ma et al. 2004, Ma et al. 2005; Desai et 
al. 2010; Malabadi et al. 2011). Various 
methods have been adopted to modify the N-
glycosylation pattern in plants. The most 
common approach is the fusion of the ER-
retention signal KDEL and production of 
knock out mutant lines  in Arabidopsis and a 
moss plant, Physcomitrella patens, which 
synthesize N-glycans lacking immunogenic 
xylose and fucose epitope (Koprevova et al. 
2004; Kang et al. 2008; Obembe et al. 2011; 
Malabadi et al. 2011). Furthemore, synthesis 
of sialic acid in plant and sialyation of plant-
expressed protein has also been reported 
(Castilho et al. 2010; Obembe et al. 2011). 
These studies have clearly indicated the 
potentialities of the plants for the production 
of glycosylated proteins with native 
biological activities for the development of 
vaccine antigens against human diseases. In 
one of the earlier studies, as reported by 
Palacpac and coworkers (1999), transgenic  
tobacco BY2 suspension-cultured cells were 
produced by the transfer of the full-length 
human galactosyl-transferase gene placed 
under the control of the cauliflower mosaic 
virus 35S promoter (Palacpac et al. 1999).  The 
transformants  were analyzed and confirmed 
that the highest level of enzymatic activity 
has glycans with galactose residues at the 
terminal non-reducing ends (Palacpac et al. 
1999). This study has clearly reported the 
successful modification of the plant cell N-
glycosylation pathway, which also led to the 
conclusion that plant glycan structures could 
be modified successfully (Palacpac et al. 1999; 
Hellwig et al. 2004; Bosch and Schots, 2010). 
This is the first proof of concept showing the 
production of a mammalian glycosyl-
transferase can alter the glycosylation 
pathway of plant cells (Palacpac et al. 1999). 
 
Current status of plant derived vaccines in 
pharmaceutical industry  
  Some of the plant derived vaccine 
antigens could soon reach the commercial 
production level in order to meet the 
demands of the immunization programmes 
because of their higher immune efficiencies 
not only in animal models but also in ferrets 
or non-human primates too (Yusibov and 
Rabindran, 2008; Tiwari et al. 2009;Gomez et 
al. 2010; Malabadi et al. 2011). A review article 
published by Tiwari and co-workers (2009) in 
a journal viz. Biotechnology Advances has 
highlighted the outcome and results of the 
most of the clinical trials of plant derived 
vaccines (Malabadi et al. 2011). The results of 
clinical trials of plant derived vaccine 
antigens have been successfully published 
and several are ready to get clearance for 
phase II trials (Yusibov and Rabindran, 2008; 
Tiwari et al. 2009; Obembe et al. 2011; 
Malabadi et al. 2011). The phase I clinical 
trials of plant derived vaccine antigens 
showed positive response in terms of safety, 
and induce sufficiently high immune 
response in healthy subjects (Tiwari et al. 
2009; Obembe, 2010; Malabadi et al. 2011). 
The clinical trials of hepatitis surface B 
antigen expressed in potato (Arizona State 
University, USA and Roswell Park Cancer 
Institute, USA), and lettuce (Thomson 
Jefferson University) also confirmed the 
boosting of anti-HBsAg antibodies in serum 
(Thanavala et al. 2005; Tiwari et al. 2009; 
Obembe et al. 2011; Malabadi et al. 2011). The 
transgenic lettuce expressing HBsAg also 
triggered specific serum-IgG response at 
levels considered to be protective (Kapusta et 
al. 1999; Tiwari et al. 2009; Obembe, 2010). 
Increased serum rabies-specific IgA 
antibodies were detected in human 
volunteers against rabies vaccine antigen 
made in spinach by using plant viral vectors 
(Thomas Jefferson University, USA) (Tiwari 
et al. 2009; Obembe, 2010; Obembe et al. 2011). 
Clinical trials on pigs using corn derived 
 




edible vaccine antigen for transmissible 
gastroenteritis virus by ProdiGene (USA) 
(Lamphear et al. 2004; Tiwari et al. 2009). They 
found neutralizing antibodies in piglets. This 
vaccine antigen was found to be effective in 
boosting lactogenic immunity (Tiwari et al. 
2009; Obembe et al. 2011). Human intrinsic 
factor, to be used against vitamin B12 
deficiency which was produced in transgenic 
A. thaliana has been taken up for the phase II 
clinical trials by Meristem Therapeutics, 
France (Tiwari et al. 2009; Obembe et al. 2011). 
The CaroRx antibody expressed in transgenic 
tobacco against dental caries has been 
submitted for phase II clinical trials by Planet 
Biotechnology Company (Tiwari et al. 2009; 
Obembe et al. 2011; Obembe, 2010). One of 
the US based company viz. Dow Agro 
Sciences LLC received regulatory approval 
for a plant-made vaccine from the USDA’s 
Centre for Veternary Biologists in 2006 
(Tiwari et al. 2009; Obembe et al. 2011; 
Malabadi et al. 2011). This plant culture 
derived veterinary vaccine antigen that 
protects poultry from Newcastle disease 
(www.thepoultrysite.com) also met the 
requirements of FDA (Tiwari et al. 2009; 
Obembe et al. 2011). The transgenic plant-
derived LTB antigen was the first antigenic 
protein used in the phase I human clinical 
trials approved by FDA. During the trial, 
human volunteers fed on potato tubers 
(Arizona State University, USA) or corn seeds 
(Prodigene, USA) genetically engineered 
against diarrhea-causing E. coli, showed the 
appearance of anti-LTB antibodies in both 
mucus and serum (Tacket et al. 1998; Tacket, 
2005; Tiwari et al. 2009; Obembe et al. 2011). In  
phase I clinical trial, transgenic potato tubers 
carrying a gene for Norwalk virus capsid 
protein (NVCP) fed to human volunteers at 
Boyce Thompson Institute for Plant Research 
USA, and confirmed the development of anti-
NVCP antibodies in serum (IgG, IgM) and 
stool (IgA) (Tacket et al. 2000; Tiwari et al. 
2009;Obembe, 2010; Obembe et al. 2011; 
Malabadi et al. 2011). In another 
development, the HBsAg expressed in 
transgenic potato at Arizona State University, 
USA and the Non-Hodgkin’s lymphoma 
antigen expressed in tobacco at Large- Scale- 
Biotechnology, USA has been submitted for 
phase II clinical trials (Basaran and 
Rodriguez-Cerezo, 2008; Tiwari et al. 2009; 
Obembe et al. 2011; Malabadi et al. 2011). FDA 
also approved the first plant derived 
injectable purified antibody fragments as a 
vaccine in human trials for non-Hodgkin 
lymphoma therapy as an efficient route of 
immunization (McCormick and Palmer, 2008; 
Tiwari et al. 2009; Obembe et al. 2011). In 
another development, a Canadian based 
company SemBioSys has completed Phase II 
trials of insulin produced in transgenic 
safflower, and have filed an Investigational 
New Drug Application with the FDA, and 
submitted a Clinical Trial Application to 
European authorities (SemBioSys 2009; 
Penney et al. 2011). Medicago Inc (Canada) 
are currently undergoing Phase II trials for 
their avian influenza vaccine produced 
transiently in tobacco, after receiving 
clearance from Health Canada (Medicago 
2010; Penney et al. 2011). Taliglucerase alfa 
produced in stable carrot cell cultures is used 
to treat Gaucher disease. Protalix Bio-
Therapeutics has just completed a Phase III 
trial  and the product was approved by the 
U.S Food and Drug Administration (FDA), 
who have since accepted a New Drug 
Application and granted a Prescription Drug 
User Fee Act action date in early 2011 
(Protalix BioTherapeutics 2010; Penny et  al. 
2011). Therefore, results of clinical trials 
confirmed the potentiality of transgenic plant 
biotechnology in diagnostic and therapeutic 
industry. Plant derived vaccines will likely 
replace the traditional vaccines in pharma-
ceutical industry in the future (Tiwari et al. 
2009; Penny et al. 2011; Obembe, 2010; 
Obembe et al. 2011; Malabadi et al. 2011). 
 
 




Disadvantages of plant derived vaccine 
antigens 
 Plant derived vaccine antigens have 
many challenges. The major limitation of this 
system is the relatively low protein yields, 
protein degradation and incorrect post-
translational modifications of protein (Daniell 
et al. 2009; Tiwari et al. 2009; Desai et al. 2010; 
Malabadi et al. 2011). Recently these issues 
have been addressed by improving the 
protein expression levels in plants by some of 
the important steps by using ER retention 
signal sequences like KDEL and HDEL, by 
the use of a leader sequence, choice of 
promoter, choice of vectors, copy number, 
methods of transformation, integration, 
stability of a transgene, transcription, role of 
introns, codon optimization and translation 
(Desai et al. 2010; Malabadi et al. 2011).  
Development of codon optimized gene’s for 
plants during expression studies have 
improved the protein yields up to 200mg/g 
Fw of plant tissue.  This high expression level 
was achieved by combination of several 
factors viz. by inserting the plant signal 
peptide at the N-terminal end, and C-
terminal endoplasmic reticulum (ER) 
retention sequence for plants (Saejung et al. 
2007). There are other efforts to avoid non-
mammalian glycosylation patterns include 
the prevention of late glycosylation by 
directing proteins to the endoplasmic 
reticulum through addition of KDEL 
sequence-tags, introduction of point 
mutations to eliminate glycosylation 
completely, or the humanization of the plant 
glycosylation machinery (Hellwig et al. 2004; 
Malabadi et al. 2011). Expression of protein in 
ER has drastically reduced the degradation, 
and resulted in the higher yield of protein 
accumulation (Desai et al. 2010; Tiwari et al. 
2009; Malabadi et al. 2011). Gene silencing is 
another major problem during the expression 
of vaccine antigenic proteins in transgenic 
plants. This is resolved by the use of 
Agrobacterium, which tends to result in fewer 
copies of transgenes than biolistic 
transformation (Malabadi and Nataraja, 
2007a; Tiwari et al. 2009; Desai et al. 2010; 
Malabadi et al. 2011). Biosafety, risk 
assessment, and public acceptance of 
transgenic plants producing vaccine antigens 
is another issue, which have to be dealt and 
widely discussed by other researchers 
somewhere, which is beyond the scope of this 
review paper (Malabadi et al. 2011).  
Furthermore, cross contamination of 
transgenic plants with other food crops was 
resolved by applying the containment 
approached-technology, thus limiting the 
environmental exposure of transgenic 
products (Tiwari et al. 2009; Malabadi et al. 
2011).     
 
Concluding remarks 
Plant derived vaccine antigens could 
be produced at a larger quantity and found to 
be properly assembled and functional (Ma et 
al. 2005). Dendritic cell targeting approach 
using plant derived vaccine antigen may play 
an important role (Malabadi et al. 2011). This 
would help in the early diagnostic tests in the 
patients suffering from human infectious 
diseases. Nevertheless, there is a major 
difference between plant and animal 
glycosylation steps in terms of complex 
glycans, but till today there is no report of 
loss of any structure or function of expressed 
proteins in plants (Palacpac et al. 1999; Ma et 
al. 2005; Bosch and Schots, 2010; Malabadi et 
al. 2011). As discussed and reviewed by many 
research workers that, the use of plants as a  
platform for the production of novel 
antigenic proteins has a major advantage in 
terms of scale up, cost effectiveness, and 
enormous amount of desired protein could be 
produced (Ma et al. 2005;Obregon et al. 2006). 
Further growth requirements of the plants are 
very simple as compared to bacteria and 
animal cells, which require costly chemicals, 
equipment and technically- trained 
manpower (Ma et al. 2005). Therefore, use of 
 




plants is more feasible and considered as one 
of the potential expression system since 
plants avoids many of the  safety and ethical 
issues (for example use of animals) associated 
with other expression systems such as 
contaminating mammalian viruses or prions 
(Ma et al. 2005; Malabadi et al. 2011). In this 
latter regard, it was mentioned earlier and 
discussed widely that, scientists in Cuba have 
developed the facilities for producing a 
monoclonal antibody at the rate of 15 g/ 
week (Ma et al. 2005). This alone will spare 
the use of 300,000 mice per year, and found to 
be very expensive. On the other hand use of 
plants could save lots of money and fairly 
invested for vaccine antigenic protein 
(Malabadi et al. 2011). 
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